Loading…
Makes plasma-derived immunoglobulin therapies for immunodeficiency and infectious disease patients.
Makes plasma-derived immunoglobulin therapies for immunodeficiency and infectious disease patients.
Collects plasma at its own centres, manufactures the immunoglobulin products itself, and sells them through specialty distributors, so profit depends on how much finished product each batch of plasma yields and on plasma cost. It bought its Boca Raton plasma and manufacturing assets from Biotest, a German company, in 2017.
Moat: narrow (regulatory licence, scale, installed base). FDA-licensed plasma collection and fractionation capacity is capital-intensive and slow to replicate.
Headquarters: Ramsey, New Jersey, US · Founded: 2004 · Employees: 647
Size ADMA Biologics (ADMA) is a United States Health Care company (Biotechnology) with a market value of $2.85B, the 1583rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $12.73 on 6 Nov 2026.
Performance Over six months the shares gained 55.8%, against -5.8% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 8.0% over the last twelve months (peer median +4.6%); the operating margin is 42.3% (peer median -42.1%).
Valuation It trades at 15.7× forward earnings against a peer median of 52.3× (cheapest of 7).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +65%, so the hurdle is -65 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 28.0 points above its cost of capital (7.9% WACC).
Short interest Short interest is 8.7% of the free float (15 Oct 2026).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $512M | $510M | $426M | $258M | $154M |
| Revenue growth | — | +20% | +65% | +68% | — |
| Gross profit | $331M | $293M | $219M | $88.2M | $34.5M |
| EBITDA | $224M | $200M | $147M | $30.0M | -$32.5M |
| Net income | $169M | $147M | $198M | -$28.2M | -$65.9M |
| Free cash flow | $116M | $27.8M | $110M | $4.03M | -$73.4M |
| Capital expenditure | $20.5M | $22.9M | $8.57M | $4.98M | $13.9M |
| Total debt | $204M | $79.9M | $82.1M | $141M | $154M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ADMA Biologics ADMA | $2.85B | +56% | +8% | 42% | 15.7× | -0.8% |
| Grifols GRF.MC | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% |
| Takeda Pharmaceutical 4502.T | $66.4B | +24% | +6% | 18% | 42.1× | 3.0% |
| Kamada KMDA | $417M | -15% | +11% | 14% | 15.8× | 4.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ADMA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +23.2% | -6.6% | 4th highest of 21 |
| 6-month return | +55.8% | -5.8% | 4th highest of 20 |
| Distance from 52-week high | -37.8% | -27.9% | 8th lowest of 21 |
| Revenue growth (TTM) | +8.0% | +4.6% | 8th highest of 17 |
| Operating margin | 42.3% | -42.1% | highest of 17 |
| Forward P/E | 15.7× | 52.3× | cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | -0.8% | 15.9% | 2nd least demanding of 5 |
| Growth delivered (Del g) | +64.6% | +31.7% | 2nd highest of 5 |
| Hurdle (Req g minus delivered) | -65.4 pp | -32.5 pp | least demanding of 5 |
| ROIC minus cost of capital | +28.0 pp | -11.0 pp | highest of 15 |
| EV / EBITDA | 13.0× | 60.2× | 2nd cheapest of 5 |
| Net debt / EBITDA | 0.3× | 3.4× | 3rd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ADMA Biologics ADMA | United States | $2.85B | +56% | +8% | 42% | 15.7× | -0.8% | +64.6% |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.85B | -9% | +20% | -3% | n/a | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.91B | +74% | +37% | 21% | 77.2× | n/a | n/a |
| Zai Lab 9688.HK | Hong Kong | $2.92B | +13% | +5% | -59% | n/a | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.93B | +27% | -3% | 16% | 17.1× | -2.0% | +27.4% |
| Xeris Biopharma XERS | United States | $2.77B | +133% | +36% | 11% | 67.9× | 33.3% | +70.2% |
| Xiamen Amoytop Biotech 688278.SS | China | $2.76B | -23% | +18% | 27% | 16.2× | 0.5% | +36.0% |
| Beam Therapeutics BEAM | United States | $2.73B | -18% | +163% | -268% | n/a | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.71B | -12% | -23% | 5% | 381.7× | 31.3% | -3.8% |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.01B | -37% | -54% | -6,983% | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.68B | -52% | 0% | -25% | n/a | n/a | n/a |
| Xencor XNCR | United States | $2.66B | +178% | -29% | -206% | n/a | n/a | n/a |
| HLB 028300.KS | South Korea | $3.06B | -49% | +29% | -96% | n/a | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.59B | -28% | -55% | -415% | n/a | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.58B | n/a | n/a | n/a | n/a | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.53B | +45% | -100% | n/a | n/a | n/a | n/a |
| Denali Therapeutics DNLI | United States | $3.22B | +2% | n/a | -2,488% | n/a | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $3.22B | -6% | +27% | -1% | 36.8× | n/a | n/a |
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| XtalPi 2228.HK | Hong Kong | $3.35B | -34% | +4% | -127% | n/a | n/a | n/a |
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |